COMMUNIQUÉS West-GlobeNewswire

Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
12/01/2026
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated [...]
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
12/01/2026
New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 [...]
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
12/01/2026
Appoints Medical Technology Veteran Karen N. Prange to Board of Directors SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind [...]
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
12/01/2026
Limited Market Release (LMR) of the LIBERTY ® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass., Jan. 12 [...]
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
12/01/2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
Polarean Highlights New CHEST Journal Study Demonstrating Xenon MRI Predicts Cystic Fibrosis Exacerbations
12/01/2026
Findings Show Xenon MRI Ventilation Defects Independently Predicts Exacerbation Risk Beyond Conventional Clinical Measures DURHAM, NC and London, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Polarean, a commercial-stage medical [...]
Nurses Ranked Most Trusted Profession for 24th Consecutive Year
12/01/2026
American Nurses Association celebrates Gallup Poll results reaffirming nurses’ national leadership and public trust Silver Spring, MD, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA) celebrates [...]
Kraig Biocraft Laboratories Takes Possession of Third Rearing Center, Completing Core Infrastructure Upgrades for 2026 Production Scale-Up
12/01/2026
ANN ARBOR, Mich., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it has [...]
Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors
12/01/2026
Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from institutional and strategic [...]
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
12/01/2026
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
BillionToOne Provides Guidance for 2026
12/01/2026
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
12/01/2026
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- [...]
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
12/01/2026
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), [...]
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
12/01/2026
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences IRVINE, CA – January 12, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
12/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 12 January 2026 at 15:00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Cabaletta Bio Announces 2026 Strategic Priorities
12/01/2026
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to [...]
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
12/01/2026
New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new [...]
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
12/01/2026
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during [...]
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
12/01/2026
Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 [...]

Pages